Ionis Pharmaceuticals Drops Another After Phase 3 Setback
Ionis Pharmaceuticals dropped again after a Phase 3 failure in transthyretin amyloid cardiomyopathy, triggering a bro...
Explore the primary drivers of risk in Dividend Aristocrats ETF, including sector shifts and interest-rate impacts, with practical mitigation tips.
26,217 articlesIonis Pharmaceuticals dropped again after a Phase 3 failure in transthyretin amyloid cardiomyopathy, triggering a bro...
Hyperliquid’s hip-3 markets surge has pushed HIP-3’s share of perpetual futures volume to roughly half, signaling a d...
BitMine posted a strong ETH staking quarter, but a large derivatives loss erased gains, underscoring risk in its Ethe...
As crypto markets face renewed volatility, USDT and USDC remain the two dominant stablecoins. This article weighs res...
AD Mortgage has sent a policy letter to the FHFA raising concerns about proposed condo financing criteria changes for...
SpaceX plans a $135-per-share IPO that could push its value to $1.77 trillion, potentially the largest U.S. listing e...
As SpaceX and other tech contenders loom large in markets, index funds gain ground and 401K savers feel the impact. H...
The SPCX IPO surged on debut, lifting sentiment across equities. Investors are eyeing non-SPCX opportunities as the m...
Meta is pulling ahead in the AI talent race as policy headwinds tighten, placing Anthropic on the defensive and rattl...
Celebrity wedding chatter isn’t just gossip—it's a gold mine of budget lessons. This deep dive uses Taylor Swift Trav...
Ready to stop reacting to retirement myths? This guide shows you how to win the retirement game: take control with co...
A high-profile MEV attack on the jaredfromsubway.eth wallet coincides with Vitalik Buterin's push to curb these explo...